Hautala, J. 2010. Cooperative Group Financial, Organizational and Management Analysis. Presentation to the NCI Clinical Trials and Translational Research Advisory Committee, September 21. http://deainfo.nci.nih.gov/advisory/ctac/0910/presentations/Hautala.pdf (accessed April 21, 2011).

IOM (Institute of Medicine). 2010. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press.

Jones, S., F. A. Holmes, J. O’Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, W. J. Hyman, D. A. Richards, R. G. Mennel, K. A. Boehm, W. G. Meyer, L. Asmar, D. Mackey, S. Riedel, H. Muss, and M. A. Savin. 2009. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared to doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. Journal of Clinical Oncology 27(8):1177-1183.

Kanarek, N. F., H. L. Tsai, S. Metzger-Gaud, D. Damron, A. Guseynova, J. F. Klamerus, and C. M. Rudin. 2010. Geographic proximity and racial disparities in cancer clinical trial participation. Journal of the National Comprehensive Cancer Network 8(12):1343-1351.

Klabunde, C. N., N. L. Keating, A. L. Potosky, A. Ambs, Y. He, M. C. Hornbrook, and P. A. Ganz. 2011. A population-based assessment of specialty physician involvement in cancer clinical trials. Journal of the National Cancer Institute 103(5):384-397.

Klamerus, J. F., S. S. Bruinooge, X. Ye, M. L. Klamerus, D. Damron, D. Lansey, J. C. Lowery, L. A. Diaz, Jr., J. G. Ford, N. Kanarek, and C. M. Rudin. 2010. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clinical Cancer Research 16(24):5997-6003.

Korn, E. L., B. Freidlin, M. Mooney, and J. S. Abrams. 2010. Accrual experience of National Cancer Institute Cooperative Group Phase III trials activated from 2000 to 2007. Journal of Clinical Oncology 28(35):5197-5201.

Kwak, E. L., Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, and A. J. Iafrate. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 363(18):1693-1703.

Moss, A. J., C. W. Francis, and D. Ryan. 2011. Collaborative clinical trials. New England Journal of Medicine 364(9):789-791.

NCI (National Cancer Institute). 2005. Report of the clinical trials working group of the National Cancer Advisory Board: Restructuring the National Cancer Clinical Trials Enterprise. Bethesda, MD: National Cancer Institute.

———. 2010. Report of the operational efficiency working group of the Clinical Trials and Translational Research Advisory Committee: Compressing the timeline for cancer clinical trial activation. Bethesda, MD: National Cancer Institute.

Perry, M. C., R. L. Comis, and R. L. Schilsky. 2008. Introduction: Contributions of the cooperative groups. Seminars in Oncology 35(5):459.

Research!America. 2010. Research enterprise survey. http://www.researchamerica.org/uploads/ResearchEnterprisePoll.pdf (accessed April 20, 2010).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement